Four mouse monoclonal antibodies directed against furosemide have been isolated and characterized. The cross-reactivity of the antibodies with eight compounds which are structurally and/or functionally related to furosemide was determined using a competition ELISA. All of the compounds, including furosemide, were then modeled using molecular mechanical and quantum mechanical methods in an attempt to correlate antibody binding with the conformational and electronic properties of the molecules. The results of these experiments demonstrated that all of the cross-reactivity observed could be readily explained using these techniques. Furthermore, these results should allow for more accurate prediction of unexpected cross-reactivities with these antibodies when they are used in immunoassays for determination of furosemide.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0161-5890(94)90087-6 | DOI Listing |
Front Immunol
March 2025
Department of Orthopaedic Medical Center, The Second Norman Bethune Hospital of Jilin University, Changchun, Jilin, China.
Multiple myeloma (MM) is a malignant disease of plasma cells that accounts for approximately 10% of all hematological malignancies and is characterized by a clonal proliferation of malignant plasma cells in the bone marrow. Numerous therapeutic strategies, including proteasome inhibitors, immunomodulators, monoclonal antibodies against CD38 and autologous stem cell transplantation, have prolonged the median survival of MM patients. Nevertheless, almost all MM patients suffer disease relapses due to drug resistance and eventually die from MM or MM-related complications.
View Article and Find Full Text PDFInt J Mol Sci
February 2025
Department of Biochemistry, Faculty of Medicine, University of Szeged, 6720 Szeged, Hungary.
Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, arises from skeletal muscle cells that fail to differentiate terminally. Two subgroups of RMS, fusion-positive and fusion-negative RMS (FPRMS and FNRMS, respectively), are characterized by the presence or absence of the fusion gene. RMSs frequently exhibit increased expression of human epidermal growth factor receptor-2 (HER2).
View Article and Find Full Text PDFBiomed Pharmacother
March 2025
Group of Pathophysiology and Therapies for Vision Disorders, Príncipe Felipe Research Center (CIPF), Eduardo Primo Yúfera 3, Valencia 46012, Spain; Joint Research Unit on Rare Diseases CIPF-Health Research Institute Hospital La Fe (IIS-La Fe), Valencia 46026, Spain; Biomedical Research Networking Center in Rare Diseases (CIBER-ER), Institute of Health Carlos III, Monforte de Lemos, 3-5. Pabellón 11, Madrid 28029, Spain; Catholic University of Valencia (UCV), Faculty of Health Sciences, Quevedo, 2, Valencia 46001, Spain. Electronic address:
Retinitis pigmentosa is a genetically heterogeneous retinal degeneration process. There is hardly any treatment available. It is associated with extensive chronic inflammation and the release of proinflammatory cytokines such as TNFα.
View Article and Find Full Text PDFJ Immunol
February 2025
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Several vaccines and immunization strategies, including inactivated vaccines, have proven effective in eliciting antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), providing an opportunity to characterize the antibody response. In this study, we investigated the monoclonal antibody responses elicited by wild-type SARS-CoV-2 inactivated vaccination compared to those elicited by natural infection and mRNA vaccination. The analysis showed that antibodies encoded by biased germline genes were shared between SARS-CoV-2 vaccinated and naturally infected individuals.
View Article and Find Full Text PDFJ Appl Lab Med
March 2025
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Biomarker and Heart Failure Clinical Trials, Baim Institute for Clinical Research, Boston, MA, United States.
Background: N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurement has class 1, level of evidence A recommendations in heart failure (HF) guidelines for diagnosis and prognosis. Analytical characterization of a novel automated NT-proBNP assay is necessary to examine its fitness for validation in pivotal clinical trials.
Methods: The Access NT-proBNP assay is an immunoenzymatic assay using monoclonal capture and detection reagents on the DxI 9000 Immunoassay Analyzer.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!